Zura Bio Limited (ZURA) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Zura Bio Limited (ZURA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Zura Bio Limited, the average estimate for 2030 earnings per share is −$0.70; 6 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Zura Bio Limited (ZURA) forecast — frequently asked questions
What is the analyst price target for Zura Bio Limited?
Analysts covering Zura Bio Limited (ZURA) have a consensus price target of $20.00, 1841.7% above the current price of $1.03. Published targets range from $20.00 to $20.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Zura Bio Limited's earnings?
The average analyst estimate for Zura Bio Limited (ZURA) earnings per share in 2030 is -0.70, with individual estimates between -0.70 and -0.70.
How much revenue is Zura Bio Limited expected to make?
Analysts forecast Zura Bio Limited (ZURA) revenue of $133.04M in 2030, based on 2 published estimates.
How many analysts cover ZURA?
6 analysts contribute estimates for Zura Bio Limited (ZURA). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.